Company intelligence / Profile preview

MinervaX

Ownership: Private
Development stage: Other

Overview

Successfully completed two Phase II clinical trials of its maternal vaccine against GBS with positive data demonstrating an acceptable safety profile in pregnant people and their infants, with high immunogenicity, leading to functionally active antibodies. The company is preparing to commence Phase III clinical trials.

Therapeutic areas: Infectious Diseases
Modalities: Protein-based vaccine
Industry: Biotech

Drug pipeline

6 assets

GBS-NN/NN2 vaccine

5 more assets in the full pipeline.

Partnerships

Wacker Biotech (manufacturing collaboration)

Beyond the preview

Go deeper on MinervaX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MinervaX.